BOSTON and ROLLE, Switzerland, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (NASDAQ: SOPH) today announced that Jurgi Camblong, PhD., Chief Executive Officer and Co-founder, is scheduled to present at the J.P. Morgan 2024 Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PST in San Francisco.
Live, listen-only webcasts of this presentation can be accessed by visiting the Investors section of the SOPHiA GENETICS website at ir.sophiagenetics.com. A replay of the webcast will be available shortly after the conclusion of the presentation and archived on the company's website for two weeks following the presentation.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on X, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
Investor Contact:
Kellen Sanger
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Kelly Katapodis
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$3.73 |
| Daily Change: | -0.10 -2.61 |
| Daily Volume: | 6,594 |
| Market Cap: | US$246.960M |
September 14, 2024 September 12, 2024 September 12, 2024 September 10, 2024 September 05, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
